Black Diamond Therapeutics Inc (NASDAQ: BDTX) is 92.53% higher on its value in year-to-date trading and has touched a low of $1.43 and a high of $6.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BDTX stock was last observed hovering at around $4.65 in the last trading session, with the day’s gains setting it 0.76%.
Currently trading at $5.41, the stock is 19.30% and 34.83% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.08 million and changing 16.34% at the moment leaves the stock 67.14% off its SMA200. BDTX registered 181.77% gain for a year compared to 6-month gain of 56.81%. The firm has a 200-day simple moving average (SMA200) of -$2.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 15.85% loss in the last 1 month and extending the period to 3 months gives it a 91.17%, and is 19.16% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.99% over the week and 8.79% over the month.
Black Diamond Therapeutics Inc (BDTX) has around 54 employees, a market worth around $279.81M and $0.00M in sales. Distance from 52-week low is 278.32% and -21.02% from its 52-week high. The company has generated returns on investments over the last 12 months (-59.34%).
Black Diamond Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.43.The EPS is expected to grow by 7.98% this year
92 institutions hold shares in Black Diamond Therapeutics Inc (BDTX), with institutional investors hold 96.68% of the company’s shares. The shares outstanding are 51.65M, and float is at 38.11M with Short Float at 4.67%. Institutions hold 94.18% of the Float.
The top institutional shareholder in the company is Bellevue Group AG with over 8.14 million shares valued at $41.09 million. The investor’s holdings represent 15.77% of the BDTX Shares outstanding. As of Jun 29, 2023, the second largest holder is NEA Management Company, LLC with 4.45 million shares valued at $22.47 million to account for 8.63% of the shares outstanding. The other top investors are RA Capital Management, L.P. which holds 3.53 million shares representing 6.84% and valued at over $17.81 million, while Artal Group S.A. holds 3.97% of the shares totaling 2.05 million with a market value of $10.33 million.
Black Diamond Therapeutics Inc (BDTX) Insider Activity
The most recent transaction is an insider purchase by BIOTECH GROWTH N V, the company’s 10% Owner. SEC filings show that BIOTECH GROWTH N V bought 400,000 shares of the company’s common stock on Oct 17 ’23 at a price of $2.34 per share for a total of $0.93 million. Following the purchase, the insider now owns 8.52 million shares.
Black Diamond Therapeutics Inc disclosed in a document filed with the SEC on Jul 05 ’23 that Behbahani Ali (Director) bought a total of 1,000,000 shares of the company’s common stock. The trade occurred on Jul 05 ’23 and was made at $5.00 per share for $5.0 million. Following the transaction, the insider now directly holds 4.45 million shares of the BDTX stock.
Still, SEC filings show that on Jul 05 ’23, RA CAPITAL MANAGEMENT, L.P. (Director) acquired 935,850 shares at an average price of $5.00 for $4.68 million. The insider now directly holds 3,213,828 shares of Black Diamond Therapeutics Inc (BDTX).
